Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: A 52-week prospective study

Journal of Korean Medical Science

Volumn 23, Issue 1, 2008, Pages 10-17

  Suh, Guk Hee ^a,e   Hee, Yeon Jung ^b   Chang, Uk Lee ^c   Choi, Sungku ^d   Sang, Kyu Lee ^a   Ju, Young Su ^a   Byeong, Kil Yeon ^a   Lee, Nam Jin ^f   Jae, Hyun Kim ^g   Baik, Seok Kee ^h   Dae, Gwan Ko ⁱ   Kim, Young Hoon ⁱ   Jung, Ho Lee ⁱ   Hong, Inja ^d   Byoung, Hoon Oh ^j   Jae, Nam Bae ^k   Jung, Han Yong ^l   Park, Jong Han ^m  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Janssen Korea   (South Korea)

^e Hallym University Medical Center   (South Korea)

^f Jeonju Elderly Hospital   (South Korea)

^g Won Kwang Iniv   (South Korea)

^h Chung Ang University College of Medicine   (South Korea)

ⁱ Inje University   (South Korea)

^j Yonsei University College of Medicine   (South Korea)

^k Inha University School of Medicine   (South Korea)

^l Soonchunhyang University College of Medicine   (South Korea)

^m Catholic University of Daegu   (South Korea)

more..

Author keywords

Alzheimer disease; Benefit; Caregivers; Double blind method; Economy; Function; Galantamine; Randomized controlled trial; RCT; Trial

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HEALTH CARE COSTS; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 40549134510     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.1.10     Document Type: Article

References (32)

1. Suh GH, Kim JK, Cho MJ. Community study of dementia in the older Korean population. Aust N Z J Psychiatry 2003; 37: 606-12.
2. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wof V, Kosley RW Jr, Davis L, Vargas HM. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-38.
3. Chu LW, Yik PY, Mok W, Chung CP. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Int J Clin Pract 2007; 61: 403-10.
4. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre trial. Eur J Neurol 2004; 11: 734-41.
5. Suh GH, Jung HY, Lee CU, Oh BH, Bae JN, Jung HY, Ju YS, Yeon BK, Park J, Hong I, Choi S, Lee HJ. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Ther 2004; 26: 1608-18.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.: Washington, DC.: American Psychiatric Association, 1994.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
9. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
10. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-81.
11. Suh GH. Development of the Korean version of the Disability Assessment for Dementia Scale. J Korean Geriatr Soc 2003; 7: 278-87.
12. Suh GH. Validation of the Korean version of the Alzheimer's Disease Assessment Scale. J Korean Geriatr Soc 2003; 7: 267-77.
13. Reisberg B, Borenstein J, Salob S, Ferris S, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (Suppl): 9-15.
14. Suh GH, Son HG, Shin H, Kim IM, Hong S, Park J, Choi IG, Kim SK, Yeon BK. Reliability and analysis of symptom category scores of the behavior pathology in Alzheimer's disease rating scale, Korean version (BEHAVE-AD-K). J Korean Geriatr Psychiatry 2001; 5: 50-7.
15. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
16. Beecham J, Knapp M. Costing psychiatric interventions. In Thornicroft G. Measuring Mental Health Needs, 2nd edn. London:, Gaskell, 2001; 200-24.
17. Wimo A, Mastey V, Winblad B. Evaluation of the healthcare resource utilization and caregiver time in antidementia drug trials-a quantitative battery. In Wimo A, Jonsson B, Karlsson G, Winblad B, editors, Health economics of dementia. Chichester, UK: John Wiley & Sons 1998; 465-99.
18. Hyoplus. WWW document: Available from: http://www.koreanursing.co.kr/ service/service_gasa.php [Accessed March 20, 2006].
19. Choi BH, Sunwoo D, Choi HM. Report on the introduction of public long-term care insurance for the elderly in Korea. Seoul: Korean Institute of Health and Social Affairs, 2001.
20. National Health Insurance Corporation. Year 2002 National Health Insurance Statistical Yearbook. Seoul: National Health Insurance Corporation, 2003.
21. Ministry of Health and Welfare. Guideline for health and welfare program for the Elderly. Seoul: Ministry of Health and Welfare, 2004.
22. June KJ, Park JY. Cost-effectiveness analysis of home health care program for cerebrovascular accident patients. J Korean Community Nursing 2001; 12: 22-31.
23. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-76.
24. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantmine International-1 Study Group. BMJ 2000; 321: 1445-9.
25. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95.
26. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 852-7.
27. Suh GH, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 2004; 19: 817-24.
28. Aneshensel CS, Pearlin LI, Levy-Storms L, Schuler RH. The transition from home to nursing home mortality among people with dementia. J Gerontol B Psychol Sci Soc Sci 2000; 55: S152-62.
29. Jönsson L, Jönsson B, Wimo A, Whitehouse P, Winblad B. Second international pharmacoeconomic conference on Alzheimer's disease. Alzheiemr Dis Assoc Disord 2000; 14: 137-40.
30. Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD) Galantamine treatment in Canada. Neurology 2001; 57: 972-8.
31. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14: 84-9.
32. Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis 1976; 29: 175-88.